Elliott Sigal

Elliott Sigal Overview

Investor Type Angel
Status Active
Professionals 1
Professionals
Investments 3
Exits 3
Exits

Elliott Sigal General Information

Description

Mr. Elliott Sigal serves as Venture Partner and Senior Advisor at New Enterprise Associates. He joined NEA in 2014. He also serves as Board Member & Member of Nominating, Corporate Governance Committee at Surface Oncology. He is a former Executive Vice President and Director of Bristol-Myers Squibb and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma Transformation Strategy of the company. He has been instrumental in increasing R&D productivity, developing the company's strategy in biologics and acquiring external innovation in Bristol's String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Mr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Mr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Mr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied Engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Mr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance. He is also a Board Member at Adaptimmune Therapeutics.

Contact Information

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Primary Office
  • Princeton, NJ
  • United States

Elliott Sigal Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Mersana Therapeutics 02-Mar-2015 Later Stage VC 0000 Drug Discovery Generating Revenue/Not Profitable 0000000 00000 00.0
0000000 00000000 21-Nov-2014 00000 00000 000.00 Drug Discovery Generating Revenue/Not Profitable 0000000 00000 00.0
00000000000 000000 19-Sep-2014 00000 00000 00000 Other Commercial Services Generating Revenue/Not Profitable 0000000 00000 00.0
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Elliott Sigal Exits (3)

To view Elliott Sigal‘s complete exit history, request access »
Company Name Exit Date Exit Type Exit Size
Surface Oncology 19-Apr-2018 IPO 00000
0000000 0000000000 28-Jun-2017 000 0000
00000000000 000000 06-May-2015 000 00000

Elliott Sigal Team (1)

Name Title Deals Funds Boards Office
Elliott Sigal Ph.D Angel Investor 0 0 Princeton, NJ